| Autor: |
Hocini, Hakim, Wiedemann, Aurélie, Blengio, Fabiola, Lefebvre, Cécile, Cervantes-Gonzalez, Minerva, Foucat, Emile, Tisserand, Pascaline, Surenaud, Mathieu, Coléon, Séverin, Prague, Mélanie, Guillaumat, Lydia, Krief, Corinne, Fenwick, Craig, Laouénan, Cédric, Bouadma, Lila, Ghosn, Jade, Pantaleo, Giuseppe, Thiébaut, Rodolphe, Abel, Laurent, Abrous, Amal |
| Předmět: |
|
| Zdroj: |
Journal of Clinical Immunology; Jul2023, Vol. 43 Issue 5, p882-893, 12p |
| Abstrakt: |
Purpose: Following a severe COVID-19 infection, a proportion of individuals develop prolonged symptoms. We investigated the immunological dysfunction that underlies the persistence of symptoms months after the resolution of acute COVID-19. Methods: We analyzed cytokines, cell phenotypes, SARS-CoV-2 spike-specific and neutralizing antibodies, and whole blood gene expression profiles in convalescent severe COVID-19 patients 1, 3, and 6 months following hospital discharge. Results: We observed persistent abnormalities until month 6 marked by (i) high serum levels of monocyte/macrophage and endothelial activation markers, chemotaxis, and hematopoietic cytokines; (ii) a high frequency of central memory CD4+ and effector CD8+ T cells; (iii) a decrease in anti-SARS-CoV-2 spike and neutralizing antibodies; and (iv) an upregulation of genes related to platelet, neutrophil activation, erythrocytes, myeloid cell differentiation, and RUNX1 signaling. We identified a "core gene signature" associated with a history of thrombotic events, with upregulation of a set of genes involved in neutrophil activation, platelet, hematopoiesis, and blood coagulation. Conclusion: The lack of restoration of gene expression to a normal profile after up to 6 months of follow-up, even in asymptomatic patients who experienced severe COVID-19, signals the need to carefully extend their clinical follow-up and propose preventive measures. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink